Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Deferred Income Tax?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2010 - 2021 (12 years)

Deferred Income Tax is 
-$319.2M (1Y -17.5% )

ALXN Stock Price & Deferred Income Tax

Deferred Income Tax for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Deferred Income Tax

chevron_right 2021 -$109.2M +3.0x *
( +12.3% / year avg)
chevron_left 2010 $27.2M
vertical_align_top Peak $349.5M +1.71x *
vertical_align_bottom Bottom -$493.5M
arrow_drop_up # Up Years 4 4 of 12
years up.
arrow_drop_down # Down Years 8
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2010 , or -9.0x faster than it's deferred income tax over the same period.
  • If ALXN grows it's stock at the same rate as it's deferred income tax (+12.3%/year) , it's stock price will grow +319% and hit $346.82 over the next 10 years.
  • ALXN's stock price has gone up 2 of the 4 years (+50%) it's deferred income tax were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Deferred Income Tax Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Deferred Income Tax YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $-109 -77.9% $108.72 -4.8%
    4/1/2020 $-493 170.7% $114.22 13.4%
    4/1/2019 $-182 -302.1% $100.76 -17.6%
    4/1/2018 $90 552.6% $122.24 -14.2%
    4/1/2017 $13 -83.9% $142.41 -5.6%
    4/1/2016 $85 -75.5% $150.9 -7.9%
    4/1/2015 $349 -512.8% $163.84 -1.5%
    4/1/2014 $-84 -318.3% $166.32 70.4%
    4/1/2013 $38 -54.1% $97.58 7.7%
    4/1/2012 $84 246.7% $90.57 91.0%
    4/1/2011 $24 -10.2% $47.42 89.6%
    4/1/2010 $27 - $25.02 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • A deferred income tax is a liability recorded on a balance sheet resulting from a difference in income recognition between tax laws and the company's accounting methods. For this reason, the company's payable income tax may not equate to the total tax expense reported.

    For more detailed definitions, please see Investopedia.